AstraZeneca will reduce its U.S. sales force by approximately 1,150 leadership positions and sales representatives as “part of the company’s ongoing strategy to operate its business more efficiently to best serve patients” in the U.S., according to a company statement. The layoffs comprise nearly one-quarter of the company’s U.S. sales organization, and were not included in previously announced efficiencies to the U.S. business. The move will cost between $50 and $100 million, to be ...